

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P363DB7B81A8EN.html>

Date: December 2022

Pages: 82

Price: US\$ 2,000.00 (Single User License)

ID: P363DB7B81A8EN

Abstracts

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2022, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 22, 6 and 4 respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
- Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
 - 3SBio Inc
 - Adaptimmune Therapeutics Plc
 - Advenchen Laboratories LLC
 - Aldeyra Therapeutics Inc
 - Apexian Pharmaceuticals Inc
 - Ascentage Pharma Group International
 - AstraZeneca Plc
 - BeiGene Ltd
 - Bristol-Myers Squibb Co
 - Calithera Biosciences Inc
 - Eisai Co Ltd
 - Epizyme Inc
 - F. Hoffmann-La Roche Ltd
 - Jiangsu Hengrui Medicine Co Ltd
 - Karyopharm Therapeutics Inc
 - Merck & Co Inc
 - Mirati Therapeutics Inc
 - Moleculin Biotech Inc
 - Novartis AG
 - Oncomatrix Biopharma SL
 - Open Therapeutics LLC
 - Otsuka Pharmaceutical Co Ltd
 - Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Shenzhen Chipscreen Biosciences Co Ltd

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

Tango Therapeutics Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles

(cedazuridine + decitabine) - Drug Profile

Product Description

Mechanism Of Action

afamitresgene autoleucel - Drug Profile

Product Description

Mechanism Of Action

AL-2846 - Drug Profile

Product Description

Mechanism Of Action

Annamycin - Drug Profile

Product Description

Mechanism Of Action

APG-115 - Drug Profile

Product Description

Mechanism Of Action

APX-3330 - Drug Profile

Product Description

Mechanism Of Action

axitinib - Drug Profile

Product Description

Mechanism Of Action

camrelizumab - Drug Profile

Product Description

Mechanism Of Action

cobimetinib fumarate - Drug Profile

Product Description

Mechanism Of Action

CS-2164 - Drug Profile

Product Description

Mechanism Of Action

ecubectedin - Drug Profile

Product Description
Mechanism Of Action
eribulin mesylate - Drug Profile
Product Description
Mechanism Of Action
everolimus - Drug Profile
Product Description
Mechanism Of Action
ganetespib - Drug Profile
Product Description
Mechanism Of Action
HSV-1716 - Drug Profile
Product Description
Mechanism Of Action
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
MRTX-9768 - Drug Profile
Product Description
Mechanism Of Action
OMTX-703 - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
pamiparib - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action

pexidartinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

selinexor - Drug Profile

Product Description

Mechanism Of Action

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

sitravatinib malate - Drug Profile

Product Description

Mechanism Of Action

SSGJ-609A - Drug Profile

Product Description

Mechanism Of Action

tazemetostat hydrobromide - Drug Profile

Product Description

Mechanism Of Action

telaglenastat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

TNG-908 - Drug Profile

Product Description

Mechanism Of Action

TQB-3234 - Drug Profile

Product Description

Mechanism Of Action

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by 3SBio Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Adaptimmune Therapeutics Plc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Advenchen Laboratories LLC, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Ascentage Pharma Group International, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bristol-Myers Squibb Co, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Eisai Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Jiangsu Hengrui

Medicine Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Karyopharm
Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc,
2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Mirati Therapeutics
Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Moleculin Biotech
Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatrix
Biopharma SL, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics
LLC, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Otsuka
Pharmaceutical Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pharma Mar SA,
2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Shenzhen
Chipscreen Biosciences Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sino
Biopharmaceutical Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento
Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Tango Therapeutics
Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P363DB7B81A8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P363DB7B81A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

